Treatment of chronic lymphocytic leukemia with monoclonal
antibodies, where are we heading?

J 2015

Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?

DOUBEK, Michael a Michal ŠMÍDA

Základní údaje

Originální název

Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?

Autoři

DOUBEK, Michael (203 Česká republika, garant, domácí) a Michal ŠMÍDA (203 Česká republika, domácí)

Vydání

Expert Review of Hematology, ABINGDON, TAYLOR & FRANCIS LTD, 2015, 1747-4086

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.439

Kód RIV

RIV/00216224:14740/15:00084906

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1586/17474086.2015.1079123

UT WoS

000365125800002

EID Scopus

2-s2.0-84947611501

Klíčová slova anglicky

CD20; CD52; chronic lymphocytic leukemia; monoclonal antibodies; resistance; therapy

Štítky

podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 4. 2016 13:18, Mgr. Eva Špillingová

Anotace

V originále

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and monoclonal antibodies (mAbs) are important part of CLL treatment. The goal of this article was to summarize current literature on the position of mAbs in CLL treatment and to mention factors influencing effectiveness of mAbs in CLL. Several new mAbs have been developed and investigated in CLL over the past few years. Mainly anti-CD20 monoclonal antibodies are still used routinely in CLL therapy. Unfortunately, the clinical application of mAbs needs to be further improved. Novel combinations and sequences of mAbs with other compounds need to be studied in clinical trials in order to increase overall response rate and prolong remission duration. Mechanisms of action of mAbs or mechanisms of resistance to mAbs have to be also investigated to predict effectiveness of mAb in particular patient. 2015 © Informa UK, Ltd.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

NV15-33561A, projekt VaV

Název: Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie

Přiložené soubory

ZVV_2015_131_1318722_Treatment_of_chronic.pdf

Požádat o autorskou verzi souboru

Citovat

DOUBEK, Michael a Michal ŠMÍDA. Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? Expert Review of Hematology. ABINGDON: TAYLOR & FRANCIS LTD, 2015, roč. 8, č. 6, s. 743-764. ISSN 1747-4086. Dostupné z: https://dx.doi.org/10.1586/17474086.2015.1079123.

@article{1318722,
   author = {Doubek, Michael and Šmída, Michal},
   article_location = {ABINGDON},
   article_number = {6},
   doi = {http://dx.doi.org/10.1586/17474086.2015.1079123},
   keywords = {CD20; CD52; chronic lymphocytic leukemia; monoclonal antibodies; resistance; therapy},
   language = {eng},
   issn = {1747-4086},
   journal = {Expert Review of Hematology},
   title = {Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?},
   url = {http://www.tandfonline.com/doi/abs/10.1586/17474086.2015.1079123?journalCode=ierr20},
   volume = {8},
   year = {2015}
}

TY  - JOUR
ID  - 1318722
AU  - Doubek, Michael - Šmída, Michal
PY  - 2015
TI  - Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?
JF  - Expert Review of Hematology
VL  - 8
IS  - 6
SP  - 743-764
EP  - 743-764
PB  - TAYLOR & FRANCIS LTD
SN  - 17474086
KW  - CD20
KW  - CD52
KW  - chronic lymphocytic leukemia
KW  - monoclonal antibodies
KW  - resistance
KW  - therapy
UR  - http://www.tandfonline.com/doi/abs/10.1586/17474086.2015.1079123?journalCode=ierr20
L2  - http://www.tandfonline.com/doi/abs/10.1586/17474086.2015.1079123?journalCode=ierr20
N2  - Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and monoclonal antibodies (mAbs) are important part of CLL treatment. The goal of this article was to summarize current literature on the position of mAbs in CLL treatment and to mention factors influencing effectiveness of mAbs in CLL. Several new mAbs have been developed and investigated in CLL over the past few years. Mainly anti-CD20 monoclonal antibodies are still used routinely in CLL therapy. Unfortunately, the clinical application of mAbs needs to be further improved. Novel combinations and sequences of mAbs with other compounds need to be studied in clinical trials in order to increase overall response rate and prolong remission duration. Mechanisms of action of mAbs or mechanisms of resistance to mAbs have to be also investigated to predict effectiveness of mAb in particular patient. 2015 © Informa UK, Ltd.
ER  -

DOUBEK, Michael a Michal ŠMÍDA. Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? \textit{Expert Review of Hematology}. ABINGDON: TAYLOR \&{} FRANCIS LTD, 2015, roč.~8, č.~6, s.~743-764. ISSN~1747-4086. Dostupné z: https://dx.doi.org/10.1586/17474086.2015.1079123.

Přehled o publikaci